Levosimendan is a unique inodilator that enhances cardiac contractility while causing vasodilation — making it distinct from traditional inotropes. In this podcast, we cover the mechanism of action, dosing, clinical uses, side effects, and evidence for levosimendan, with a focus on general ICU and critical care applications. We end with practice questions!

Designed for medical students, nurses, physician assistants, nurse practitioners, respiratory therapists, and physicians, this video explains how levosimendan fits into the broader management of critically ill patients requiring inotropic support.

What you’ll learn: How levosimendan works as a calcium sensitizer and potassium channel opener. Common ICU indications and patient selection. Dosing strategies and administration tips. Side effects, monitoring, and contraindications Key evidence and clinical practice considerations. Practice questions.

📚 Related Resources:

Download our levosimendan study guide and practice questions:

https://www.patreon.com/collection/1443765

Watch next:

Playlist Vasopressors and Inotropes:

https://youtube.com/playlist?list=PLf5bMa9_tvRg_nAnm91hsyHhI0y_ahoS1&si=Myz25vHJgHAp4Nvc

👇DON'T MISS OUT - JOIN OUR PATREON COMMUNITY TODAY

https://www.patreon.com/WhiteBoardMedicine

We appreciate the support!

DISCLAIMER THIS PODCAST DOES NOT PROVIDE MEDICAL ADVICE. The information, including but not limited to, audio, text, graphics, images and other material contained on this website are for informational purposes only. No material on this site is intended to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding a medical condition or treatment and before undertaking a new health care regimen, and never disregard professional medical advice or delay in seeking it because of something you have read, watched, or listened to on this video, or any other videos, reports, texts tweets or other sources.